[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fyUWg45wj4ZcRg_YU_SLIn1mzK8nrqaONg0IfyF1feqo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":53,"rows":60},"RWTH Aachen University",[4],230,false,18,100272480,5,184,[13,16,18,21,24,26,28,30],{"name":14,"count":15},"COPD",6,{"name":17,"count":10},"Heart Failure",{"name":19,"count":20},"Asthma",4,{"name":22,"count":23},"Diaphragm Injury",3,{"name":25,"count":23},"Syncope",{"name":27,"count":23},"Schizophrenia",{"name":29,"count":23},"Diabetes Mellitus Type 2 (T2DM)",{"name":31,"count":23},"Septic Shock",[33,38,43,48],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT03334006","Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis","2027-09","Pentaglobin®\u002FStandard of Care",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02577926","The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia","2027-12","Ruxolitinib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04655235","Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia","2028-12","Genotyping",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05247814","Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients","2032-02","Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,87,105,129,154,175,243,275,298,324,342,368,386,404,422,448,473,500,518,542,568,604,631,649,674,700,727,745,763,788,806,833,858,886,912,937,955,980,1014,1039,1062,1086,1112,1137,1162,1187,1211,1235,1260,1285,1311,1336,1362],{"intervention":42,"totalTrials":62,"cells":63},1,{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":69,"PHASE3":81,"PHASE4":83,"NA":85},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[],{"trials":70,"activeCount":62,"soonestReadout":41},[71],{"nctId":39,"briefTitle":40,"status":72,"phases":73,"primaryCompletion":41,"completion":46,"start":74,"enrollment":75,"conditions":76,"interventions":79},"ACTIVE_NOT_RECRUITING",[56],"2015-10",207,[77,78],"Polycythemia Vera (PV)","Essential Thrombocythemia (ET)",[42,80],"BAT",{"trials":82,"activeCount":66},[],{"trials":84,"activeCount":66},[],{"trials":86,"activeCount":66},[],{"intervention":80,"totalTrials":62,"cells":88},{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":99,"PHASE4":101,"NA":103},{"trials":90,"activeCount":66},[],{"trials":92,"activeCount":66},[],{"trials":94,"activeCount":62,"soonestReadout":41},[95],{"nctId":39,"briefTitle":40,"status":72,"phases":96,"primaryCompletion":41,"completion":46,"start":74,"enrollment":75,"conditions":97,"interventions":98},[56],[77,78],[42,80],{"trials":100,"activeCount":66},[],{"trials":102,"activeCount":66},[],{"trials":104,"activeCount":66},[],{"intervention":37,"totalTrials":62,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":123,"PHASE4":125,"NA":127},{"trials":108,"activeCount":66},[],{"trials":110,"activeCount":66},[],{"trials":112,"activeCount":62,"soonestReadout":36},[113],{"nctId":34,"briefTitle":35,"status":114,"phases":115,"primaryCompletion":36,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"RECRUITING",[56],"2028-03","2017-11-20",200,[120,121,31],"Peritonitis","Sepsis",[37],{"trials":124,"activeCount":66},[],{"trials":126,"activeCount":66},[],{"trials":128,"activeCount":66},[],{"intervention":52,"totalTrials":62,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":141},{"trials":132,"activeCount":66},[],{"trials":134,"activeCount":66},[],{"trials":136,"activeCount":66},[],{"trials":138,"activeCount":66},[],{"trials":140,"activeCount":66},[],{"trials":142,"activeCount":62,"soonestReadout":51},[143],{"nctId":49,"briefTitle":50,"status":144,"phases":145,"primaryCompletion":51,"completion":51,"start":146,"enrollment":147,"conditions":148,"interventions":153},"NOT_YET_RECRUITING",[],"2022-07",2000,[149,150,151,152],"Polypharmacy","Pharmacogenetics","Pharmacogenomic Testing","Drug-Related Side Effects and Adverse Reactions",[52],{"intervention":47,"totalTrials":62,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":166},{"trials":157,"activeCount":66},[],{"trials":159,"activeCount":66},[],{"trials":161,"activeCount":66},[],{"trials":163,"activeCount":66},[],{"trials":165,"activeCount":66},[],{"trials":167,"activeCount":62,"soonestReadout":46},[168],{"nctId":44,"briefTitle":45,"status":114,"phases":169,"primaryCompletion":46,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":174},[],"2030-03","2021-10-01",600,[27],[47],{"intervention":176,"totalTrials":20,"cells":177},"Xenon",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":211,"NA":241},{"trials":179,"activeCount":66},[],{"trials":181,"activeCount":66},[],{"trials":183,"activeCount":66},[],{"trials":185,"activeCount":66},[186,198],{"nctId":187,"briefTitle":188,"status":189,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT01839084","PaNeX: Partial Nephrectomy Under Xenon","COMPLETED",[57],"2016-02","2013-07",46,[195],"Renal Function After Partial Nephrectomy",[176,197],"Isoflurane",{"nctId":199,"briefTitle":200,"status":189,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":210},"NCT01285271","A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon",[57],"2011-09","2011-05",30,[176,206,207,208,209],"Sevoflurane","Anesthetics, Inhalation","Coronary Disease","Coronary Artery Bypass",[176,206],{"trials":212,"activeCount":66},[213,224],{"nctId":214,"briefTitle":215,"status":216,"phases":217,"primaryCompletion":218,"completion":218,"start":219,"enrollment":66,"conditions":220,"interventions":222},"NCT03504033","Xenon-anesthesia on Patients Undergoing Major Liver-resection","WITHDRAWN",[58],"2019-09-27","2018-04-11",[221],"Liver Function After Partial Liver Resection",[176,223],"Desflurane",{"nctId":225,"briefTitle":226,"status":189,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":237},"NCT00793663","Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia",[58],"2011-04","2008-11",220,[232,233,234,235,236],"Anaesthetics Gases, Xenon","Anaesthetics Volatile, Sevoflurane","Depth of Anaesthesia","Postoperative Nausea","Postoperative Vomiting",[176,206,238,239,240,239],"Dexamethasone","NaCl","Ondansetron",{"trials":242,"activeCount":66},[],{"intervention":206,"totalTrials":23,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":267,"NA":273},{"trials":246,"activeCount":66},[],{"trials":248,"activeCount":66},[],{"trials":250,"activeCount":66},[],{"trials":252,"activeCount":66},[253,263],{"nctId":254,"briefTitle":255,"status":189,"phases":256,"primaryCompletion":191,"completion":191,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT02322502","Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia",[57],"2015-02",352,[260],"Anesthesia With Use of LMA (Laryngeal Mask Airway)",[223,206,262],"propofol",{"nctId":199,"briefTitle":200,"status":189,"phases":264,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":265,"interventions":266},[57],[176,206,207,208,209],[176,206],{"trials":268,"activeCount":66},[269],{"nctId":225,"briefTitle":226,"status":189,"phases":270,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":271,"interventions":272},[58],[232,233,234,235,236],[176,206,238,239,240,239],{"trials":274,"activeCount":66},[],{"intervention":223,"totalTrials":276,"cells":277},2,{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":290,"NA":296},{"trials":279,"activeCount":66},[],{"trials":281,"activeCount":66},[],{"trials":283,"activeCount":66},[],{"trials":285,"activeCount":66},[286],{"nctId":254,"briefTitle":255,"status":189,"phases":287,"primaryCompletion":191,"completion":191,"start":257,"enrollment":258,"conditions":288,"interventions":289},[57],[260],[223,206,262],{"trials":291,"activeCount":66},[292],{"nctId":214,"briefTitle":215,"status":216,"phases":293,"primaryCompletion":218,"completion":218,"start":219,"enrollment":66,"conditions":294,"interventions":295},[58],[221],[176,223],{"trials":297,"activeCount":66},[],{"intervention":299,"totalTrials":62,"cells":300},"Maintenance treatment",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":322},{"trials":302,"activeCount":66},[],{"trials":304,"activeCount":66},[],{"trials":306,"activeCount":66},[],{"trials":308,"activeCount":66},[],{"trials":310,"activeCount":66},[311],{"nctId":312,"briefTitle":313,"status":314,"phases":315,"primaryCompletion":316,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":320},"NCT02435095","Antipsychotic Induced Structural and Functional Brain Changes","TERMINATED",[58],"2020-08","2015-05",174,[27],[299,321],"Intermittent treatment",{"trials":323,"activeCount":66},[],{"intervention":321,"totalTrials":62,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":340},{"trials":327,"activeCount":66},[],{"trials":329,"activeCount":66},[],{"trials":331,"activeCount":66},[],{"trials":333,"activeCount":66},[],{"trials":335,"activeCount":66},[336],{"nctId":312,"briefTitle":313,"status":314,"phases":337,"primaryCompletion":316,"completion":316,"start":317,"enrollment":318,"conditions":338,"interventions":339},[58],[27],[299,321],{"trials":341,"activeCount":66},[],{"intervention":343,"totalTrials":62,"cells":344},"Telmisartan",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":366},{"trials":346,"activeCount":66},[],{"trials":348,"activeCount":66},[],{"trials":350,"activeCount":66},[],{"trials":352,"activeCount":66},[],{"trials":354,"activeCount":66},[355],{"nctId":356,"briefTitle":357,"status":314,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":365},"NCT00559286","Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels",[58],"2009-01","2007-12",40,[363,364],"Arterial Hypertension","Diabetes Mellitus Type 2 IRC or NIR",[343],{"trials":367,"activeCount":66},[],{"intervention":238,"totalTrials":62,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":384},{"trials":371,"activeCount":66},[],{"trials":373,"activeCount":66},[],{"trials":375,"activeCount":66},[],{"trials":377,"activeCount":66},[],{"trials":379,"activeCount":66},[380],{"nctId":225,"briefTitle":226,"status":189,"phases":381,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":382,"interventions":383},[58],[232,233,234,235,236],[176,206,238,239,240,239],{"trials":385,"activeCount":66},[],{"intervention":239,"totalTrials":62,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":402},{"trials":389,"activeCount":66},[],{"trials":391,"activeCount":66},[],{"trials":393,"activeCount":66},[],{"trials":395,"activeCount":66},[],{"trials":397,"activeCount":66},[398],{"nctId":225,"briefTitle":226,"status":189,"phases":399,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":400,"interventions":401},[58],[232,233,234,235,236],[176,206,238,239,240,239],{"trials":403,"activeCount":66},[],{"intervention":240,"totalTrials":62,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":420},{"trials":407,"activeCount":66},[],{"trials":409,"activeCount":66},[],{"trials":411,"activeCount":66},[],{"trials":413,"activeCount":66},[],{"trials":415,"activeCount":66},[416],{"nctId":225,"briefTitle":226,"status":189,"phases":417,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":418,"interventions":419},[58],[232,233,234,235,236],[176,206,238,239,240,239],{"trials":421,"activeCount":66},[],{"intervention":423,"totalTrials":62,"cells":424},"Treatment with entecavir",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":446},{"trials":426,"activeCount":66},[],{"trials":428,"activeCount":66},[],{"trials":430,"activeCount":66},[],{"trials":432,"activeCount":66},[],{"trials":434,"activeCount":66},[435],{"nctId":436,"briefTitle":437,"status":314,"phases":438,"primaryCompletion":439,"completion":440,"start":228,"enrollment":441,"conditions":442,"interventions":445},"NCT01341106","Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection",[58],"2015-01","2015-04",7,[443,444],"Hepatitis B, Chronic","Liver Fibrosis",[423],{"trials":447,"activeCount":66},[],{"intervention":449,"totalTrials":62,"cells":450},"Midazolam",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":471},{"trials":452,"activeCount":66},[],{"trials":454,"activeCount":66},[],{"trials":456,"activeCount":66},[],{"trials":458,"activeCount":66},[],{"trials":460,"activeCount":66},[461],{"nctId":462,"briefTitle":463,"status":189,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":470},"NCT03052660","Impact of Preoperative Midazolam on Outcome of Elderly Patients",[58],"2019-06-24","2017-10-12",782,[469],"Preanesthetic Medication",[449],{"trials":472,"activeCount":66},[],{"intervention":474,"totalTrials":62,"cells":475},"Atomoxetine",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":498},{"trials":477,"activeCount":66},[],{"trials":479,"activeCount":66},[],{"trials":481,"activeCount":66},[],{"trials":483,"activeCount":66},[],{"trials":485,"activeCount":66},[486],{"nctId":487,"briefTitle":488,"status":189,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":496},"NCT03661788","Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD",[58],"2017-12-06","2018-06-27","2016-05",38,[495],"ADHD",[474,497],"Placebos",{"trials":499,"activeCount":66},[],{"intervention":497,"totalTrials":62,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":516},{"trials":503,"activeCount":66},[],{"trials":505,"activeCount":66},[],{"trials":507,"activeCount":66},[],{"trials":509,"activeCount":66},[],{"trials":511,"activeCount":66},[512],{"nctId":487,"briefTitle":488,"status":189,"phases":513,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":514,"interventions":515},[58],[495],[474,497],{"trials":517,"activeCount":66},[],{"intervention":519,"totalTrials":62,"cells":520},"Spiolto® Respimat®",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":540},{"trials":522,"activeCount":66},[],{"trials":524,"activeCount":66},[],{"trials":526,"activeCount":66},[],{"trials":528,"activeCount":66},[],{"trials":530,"activeCount":66},[531],{"nctId":532,"briefTitle":533,"status":216,"phases":534,"primaryCompletion":535,"completion":536,"start":537,"enrollment":66,"conditions":538,"interventions":539},"NCT02812862","Cardiac Effects of Spiolto®\u002FRespimat® in Patients With Congestive Heart Failure and COPD",[58],"2017-08","2018-08","2016-08",[14],[519],{"trials":541,"activeCount":66},[],{"intervention":543,"totalTrials":62,"cells":544},"Rivaroxaban or Marcumar",{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":553,"NA":566},{"trials":546,"activeCount":66},[],{"trials":548,"activeCount":66},[],{"trials":550,"activeCount":66},[],{"trials":552,"activeCount":66},[],{"trials":554,"activeCount":66},[555],{"nctId":556,"briefTitle":557,"status":189,"phases":558,"primaryCompletion":559,"completion":559,"start":192,"enrollment":560,"conditions":561,"interventions":565},"NCT02066662","Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification",[58],"2020-03",192,[562,563,564],"Atrial Fibrillation or Pulmonary Embolism","Need of Long Term Oral Anticoagulation Therapy (OAT)","Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location",[543],{"trials":567,"activeCount":66},[],{"intervention":569,"totalTrials":276,"cells":570},"Linagliptin",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":600,"NA":602},{"trials":572,"activeCount":66},[],{"trials":574,"activeCount":66},[],{"trials":576,"activeCount":66},[],{"trials":578,"activeCount":66},[579,589],{"nctId":580,"briefTitle":581,"status":314,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT01888796","Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus",[57],"2014-12","2013-09",8,[29,587],"Left Ventricular Diastolic Dysfunction",[569],{"nctId":590,"briefTitle":591,"status":314,"phases":592,"primaryCompletion":593,"completion":594,"start":595,"enrollment":20,"conditions":596,"interventions":599},"NCT02077309","Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus",[57],"2015-09","2015-11","2014-08",[29,597,598],"Vascular Inflammation","Plaque Morphology",[569],{"trials":601,"activeCount":66},[],{"trials":603,"activeCount":66},[],{"intervention":605,"totalTrials":62,"cells":606},"Vaseline",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":627,"NA":629},{"trials":608,"activeCount":66},[],{"trials":610,"activeCount":66},[],{"trials":612,"activeCount":66},[],{"trials":614,"activeCount":66},[615],{"nctId":616,"briefTitle":617,"status":189,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT03095872","Comparison of the Effect of Vaseline and Bepanthen® \"Wund- Und Heilsalbe\" on the Wound Healing Following Laser Therapy",[57],"2018-01-22","2018-02-05","2017-03-01",37,[624],"Photodamaged Skin",[605,626],"Bepanthen",{"trials":628,"activeCount":66},[],{"trials":630,"activeCount":66},[],{"intervention":626,"totalTrials":62,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":645,"NA":647},{"trials":634,"activeCount":66},[],{"trials":636,"activeCount":66},[],{"trials":638,"activeCount":66},[],{"trials":640,"activeCount":66},[641],{"nctId":616,"briefTitle":617,"status":189,"phases":642,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":643,"interventions":644},[57],[624],[605,626],{"trials":646,"activeCount":66},[],{"trials":648,"activeCount":66},[],{"intervention":650,"totalTrials":62,"cells":651},"Vitamin K1",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":670,"NA":672},{"trials":653,"activeCount":66},[],{"trials":655,"activeCount":66},[],{"trials":657,"activeCount":66},[],{"trials":659,"activeCount":66},[660],{"nctId":661,"briefTitle":662,"status":314,"phases":663,"primaryCompletion":664,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":669},"NCT01742273","Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients",[57],"2020-07-17","2013-10",63,[668],"Cardiovascular Diseases",[650],{"trials":671,"activeCount":66},[],{"trials":673,"activeCount":66},[],{"intervention":675,"totalTrials":62,"cells":676},"Selenium Supplement",{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":696,"NA":698},{"trials":678,"activeCount":66},[],{"trials":680,"activeCount":66},[],{"trials":682,"activeCount":66},[],{"trials":684,"activeCount":66},[685],{"nctId":686,"briefTitle":687,"status":189,"phases":688,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT02530788","High-dose Selenium Supplementation in Patients With Left Ventricular Assist",[57],"2017-07","2018-01","2015-08",21,[694],"Ventricular Dysfunction, Left",[675],{"trials":697,"activeCount":66},[],{"trials":699,"activeCount":66},[],{"intervention":701,"totalTrials":62,"cells":702},"SonoVue",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":723,"NA":725},{"trials":704,"activeCount":66},[],{"trials":706,"activeCount":66},[],{"trials":708,"activeCount":66},[],{"trials":710,"activeCount":66},[711],{"nctId":712,"briefTitle":713,"status":714,"phases":715,"primaryCompletion":716,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT03385200","KVUS at Neoadjuvant CTx of Breast Cancer","UNKNOWN",[57],"2019-06-12","2019-12-12","2016-12-12",60,[721],"Early Primary Breast Cancer",[701],{"trials":724,"activeCount":66},[],{"trials":726,"activeCount":66},[],{"intervention":262,"totalTrials":62,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":741,"NA":743},{"trials":730,"activeCount":66},[],{"trials":732,"activeCount":66},[],{"trials":734,"activeCount":66},[],{"trials":736,"activeCount":66},[737],{"nctId":254,"briefTitle":255,"status":189,"phases":738,"primaryCompletion":191,"completion":191,"start":257,"enrollment":258,"conditions":739,"interventions":740},[57],[260],[223,206,262],{"trials":742,"activeCount":66},[],{"trials":744,"activeCount":66},[],{"intervention":197,"totalTrials":62,"cells":746},{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":759,"NA":761},{"trials":748,"activeCount":66},[],{"trials":750,"activeCount":66},[],{"trials":752,"activeCount":66},[],{"trials":754,"activeCount":66},[755],{"nctId":187,"briefTitle":188,"status":189,"phases":756,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":757,"interventions":758},[57],[195],[176,197],{"trials":760,"activeCount":66},[],{"trials":762,"activeCount":66},[],{"intervention":764,"totalTrials":62,"cells":765},"Xenon pro Anaesthesia 100 %",{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":784,"NA":786},{"trials":767,"activeCount":66},[],{"trials":769,"activeCount":66},[],{"trials":771,"activeCount":66},[],{"trials":773,"activeCount":66},[774],{"nctId":775,"briefTitle":776,"status":314,"phases":777,"primaryCompletion":439,"completion":439,"start":778,"enrollment":779,"conditions":780,"interventions":782},"NCT02129400","Influence on Erythropoetin-level by Xenon",[57],"2014-05",36,[781],"Healthy Volunteers",[764,783],"Aer medicinalis Linde 100%",{"trials":785,"activeCount":66},[],{"trials":787,"activeCount":66},[],{"intervention":783,"totalTrials":62,"cells":789},{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":802,"NA":804},{"trials":791,"activeCount":66},[],{"trials":793,"activeCount":66},[],{"trials":795,"activeCount":66},[],{"trials":797,"activeCount":66},[798],{"nctId":775,"briefTitle":776,"status":314,"phases":799,"primaryCompletion":439,"completion":439,"start":778,"enrollment":779,"conditions":800,"interventions":801},[57],[781],[764,783],{"trials":803,"activeCount":66},[],{"trials":805,"activeCount":66},[],{"intervention":807,"totalTrials":62,"cells":808},"Nutrition + exercise",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":829,"NA":831},{"trials":810,"activeCount":66},[],{"trials":812,"activeCount":66},[],{"trials":814,"activeCount":66},[],{"trials":816,"activeCount":66},[817],{"nctId":818,"briefTitle":819,"status":714,"phases":820,"primaryCompletion":821,"completion":822,"start":823,"enrollment":361,"conditions":824,"interventions":828},"NCT04205760","Preoperative Nutritional Optimization and Physical Exercise for Patients Scheduled for Elective Implantation for a Left-Ventricular Assist Device",[57],"2023-07-02","2023-12-02","2022-01-02",[825,826,827],"Left Ventricular Assist Device","End-stage Heart Failure","Cardiac Surgery",[807],{"trials":830,"activeCount":66},[],{"trials":832,"activeCount":66},[],{"intervention":834,"totalTrials":62,"cells":835},"Liraglutide Pen Injector [Victoza]",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":854,"NA":856},{"trials":837,"activeCount":66},[],{"trials":839,"activeCount":66},[],{"trials":841,"activeCount":66},[],{"trials":843,"activeCount":66},[844],{"nctId":845,"briefTitle":846,"status":216,"phases":847,"primaryCompletion":848,"completion":849,"start":850,"enrollment":66,"conditions":851,"interventions":853},"NCT04057261","Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease",[57],"2022-08","2022-11","2020-11",[852,668],"Type 2 Diabetes",[834],{"trials":855,"activeCount":66},[],{"trials":857,"activeCount":66},[],{"intervention":859,"totalTrials":62,"cells":860},"OLIMEL 7,6%E \u002F PeriOLIMEL 2,5%E",{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":882,"NA":884},{"trials":862,"activeCount":66},[],{"trials":864,"activeCount":66},[],{"trials":866,"activeCount":66},[],{"trials":868,"activeCount":66},[869],{"nctId":870,"briefTitle":871,"status":216,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":66,"conditions":875,"interventions":881},"NCT04012333","The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial",[57],"2022-03","2020-06",[876,877,878,879,880],"Nutritional Disorder","Critical Illness","Malnutrition","Frailty","Sarcopenia",[859],{"trials":883,"activeCount":66},[],{"trials":885,"activeCount":66},[],{"intervention":887,"totalTrials":62,"cells":888},"Octenisept and Serasept",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":908,"NA":910},{"trials":890,"activeCount":66},[],{"trials":892,"activeCount":66},[],{"trials":894,"activeCount":66},[],{"trials":896,"activeCount":66},[897],{"nctId":898,"briefTitle":899,"status":216,"phases":900,"primaryCompletion":901,"completion":901,"start":902,"enrollment":66,"conditions":903,"interventions":907},"NCT04172363","Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics",[57],"2021-05-22","2020-07-22",[904,905,906],"Decubiti","Chronic Wounds","Acute Wounds",[887],{"trials":909,"activeCount":66},[],{"trials":911,"activeCount":66},[],{"intervention":913,"totalTrials":62,"cells":914},"supportive therapy with: ACE-inhibitor \u002F ARB \u002F Statin",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":933,"NA":935},{"trials":916,"activeCount":66},[],{"trials":918,"activeCount":66},[],{"trials":920,"activeCount":66},[],{"trials":922,"activeCount":66},[923],{"nctId":924,"briefTitle":925,"status":189,"phases":926,"primaryCompletion":257,"completion":257,"start":927,"enrollment":928,"conditions":929,"interventions":931},"NCT00554502","Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy",[57],"2008-02",148,[930],"IgA Nephropathy",[913,932],"supportive and immunosuppressive therapy",{"trials":934,"activeCount":66},[],{"trials":936,"activeCount":66},[],{"intervention":932,"totalTrials":62,"cells":938},{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":945,"PHASE4":951,"NA":953},{"trials":940,"activeCount":66},[],{"trials":942,"activeCount":66},[],{"trials":944,"activeCount":66},[],{"trials":946,"activeCount":66},[947],{"nctId":924,"briefTitle":925,"status":189,"phases":948,"primaryCompletion":257,"completion":257,"start":927,"enrollment":928,"conditions":949,"interventions":950},[57],[930],[913,932],{"trials":952,"activeCount":66},[],{"trials":954,"activeCount":66},[],{"intervention":956,"totalTrials":62,"cells":957},"Ready Medical Post Treatment",{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":976,"NA":978},{"trials":959,"activeCount":66},[],{"trials":961,"activeCount":66},[],{"trials":963,"activeCount":66},[],{"trials":965,"activeCount":66},[966],{"nctId":967,"briefTitle":968,"status":216,"phases":969,"primaryCompletion":970,"completion":971,"start":972,"enrollment":66,"conditions":973,"interventions":975},"NCT03668665","Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in \"Split Wound Design\"",[57],"2020-04","2020-10","2018-10",[974],"Wound Heal",[956],{"trials":977,"activeCount":66},[],{"trials":979,"activeCount":66},[],{"intervention":981,"totalTrials":276,"cells":982},"Empagliflozin",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":984,"activeCount":66},[],{"trials":986,"activeCount":66},[],{"trials":988,"activeCount":66},[989,997],{"nctId":990,"briefTitle":991,"status":189,"phases":992,"primaryCompletion":993,"completion":993,"start":994,"enrollment":361,"conditions":995,"interventions":996},"NCT03132181","Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes",[56],"2019-01-23","2017-04-24",[29],[981],{"nctId":998,"briefTitle":999,"status":314,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1007},"NCT03554200","EMPA Acute Heart Failure",[56],"2020-10-29","2018-06-11",19,[1005,1006],"Diabetes Mellitus, Type 2","Acute Heart Failure",[981],{"trials":1009,"activeCount":66},[],{"trials":1011,"activeCount":66},[],{"trials":1013,"activeCount":66},[],{"intervention":1015,"totalTrials":62,"cells":1016},"Nicotinamide",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1018,"activeCount":66},[],{"trials":1020,"activeCount":66},[],{"trials":1022,"activeCount":66},[1023],{"nctId":1024,"briefTitle":1025,"status":216,"phases":1026,"primaryCompletion":1027,"completion":1028,"start":1029,"enrollment":66,"conditions":1030,"interventions":1032},"NCT03761511","Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia",[56],"2025-06","2025-12","2023-04",[1031],"Friedreich Ataxia",[1015],{"trials":1034,"activeCount":66},[],{"trials":1036,"activeCount":66},[],{"trials":1038,"activeCount":66},[],{"intervention":1040,"totalTrials":62,"cells":1041},"Oxytocin",{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1043,"activeCount":66},[],{"trials":1045,"activeCount":66},[],{"trials":1047,"activeCount":66},[1048],{"nctId":1049,"briefTitle":1050,"status":714,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":439,"enrollment":361,"conditions":1053,"interventions":1055},"NCT02350946","Effects of Oxytocin on Emotion Recognition and Response Inhibition",[56],"2017-01",[1054],"The Impact of Oxytocin on Social Cognition",[1040],{"trials":1057,"activeCount":66},[],{"trials":1059,"activeCount":66},[],{"trials":1061,"activeCount":66},[],{"intervention":1063,"totalTrials":62,"cells":1064},"Cabazitaxel chemotherapy",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1066,"activeCount":66},[],{"trials":1068,"activeCount":66},[],{"trials":1070,"activeCount":66},[1071],{"nctId":1072,"briefTitle":1073,"status":314,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":192,"enrollment":1076,"conditions":1077,"interventions":1079},"NCT01941550","Neoadjuvant Chemotherapy With Cabazitaxel",[56],"2016-01",11,[1078],"High-Risk Cancer",[1063],{"trials":1081,"activeCount":66},[],{"trials":1083,"activeCount":66},[],{"trials":1085,"activeCount":66},[],{"intervention":1087,"totalTrials":62,"cells":1088},"Ferric Carboxymaltose",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1090,"activeCount":66},[],{"trials":1092,"activeCount":66},[],{"trials":1094,"activeCount":66},[1095],{"nctId":1096,"briefTitle":1097,"status":189,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1105},"NCT03079518","Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency",[56],"2017-10-25","2017-03-10",23,[1103,1104],"Heart Failure, Systolic","Iron Deficiency",[1087],{"trials":1107,"activeCount":66},[],{"trials":1109,"activeCount":66},[],{"trials":1111,"activeCount":66},[],{"intervention":1113,"totalTrials":62,"cells":1114},"XIFAXAN®",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1131,"PHASE4":1133,"NA":1135},{"trials":1116,"activeCount":66},[],{"trials":1118,"activeCount":66},[],{"trials":1120,"activeCount":66},[1121],{"nctId":1122,"briefTitle":1123,"status":314,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":191,"enrollment":1126,"conditions":1127,"interventions":1130},"NCT02555293","Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection",[56],"2020-11-20",96,[1128,1129],"Malignant Liver Disease","Major Liver Resection",[1113],{"trials":1132,"activeCount":66},[],{"trials":1134,"activeCount":66},[],{"trials":1136,"activeCount":66},[],{"intervention":1138,"totalTrials":62,"cells":1139},"Xenon Inhalation",{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1141,"activeCount":66},[],{"trials":1143,"activeCount":66},[],{"trials":1145,"activeCount":66},[1146],{"nctId":1147,"briefTitle":1148,"status":314,"phases":1149,"primaryCompletion":1150,"completion":583,"start":202,"enrollment":10,"conditions":1151,"interventions":1155},"NCT01262729","Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation",[56],"2014-11",[1152,1153,1154],"Efficacy and Safety of Xenon Inhalation","Successful Cardiopulmonary Resuscitation","Addition to Therapeutical Hypothermia",[1138],{"trials":1157,"activeCount":66},[],{"trials":1159,"activeCount":66},[],{"trials":1161,"activeCount":66},[],{"intervention":1163,"totalTrials":62,"cells":1164},"Naltrexone",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1179,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1166,"activeCount":66},[],{"trials":1168,"activeCount":66},[1169],{"nctId":1170,"briefTitle":1171,"status":314,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1178},"NCT03854942","Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System",[55],"2017-12-13","2011-08-30",43,[1177],"Alcohol Addiction",[1163],{"trials":1180,"activeCount":66},[],{"trials":1182,"activeCount":66},[],{"trials":1184,"activeCount":66},[],{"trials":1186,"activeCount":66},[],{"intervention":1188,"totalTrials":62,"cells":1189},"contrast echocardiography",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1198,"NA":1200},{"trials":1191,"activeCount":66},[],{"trials":1193,"activeCount":66},[],{"trials":1195,"activeCount":66},[],{"trials":1197,"activeCount":66},[],{"trials":1199,"activeCount":66},[],{"trials":1201,"activeCount":66},[1202],{"nctId":1203,"briefTitle":1204,"status":189,"phases":1205,"primaryCompletion":1206,"completion":1206,"start":1207,"enrollment":118,"conditions":1208,"interventions":1210},"NCT00529607","Diagnostics for the Reperfusion Injury Following MI",[],"2009-03","2007-09",[1209],"Reperfusion Injury",[1188],{"intervention":1212,"totalTrials":62,"cells":1213},"Oxytocin vs. Placebo",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1215,"activeCount":66},[],{"trials":1217,"activeCount":66},[],{"trials":1219,"activeCount":66},[],{"trials":1221,"activeCount":66},[],{"trials":1223,"activeCount":66},[],{"trials":1225,"activeCount":66},[1226],{"nctId":1227,"briefTitle":1228,"status":189,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":719,"conditions":1232,"interventions":1234},"NCT01712464","Modulation of Reinforcement Learning",[59],"2016-08-07","2013-10-18",[1233],"Impact of Oxytocin on Social Learning",[1212],{"intervention":1236,"totalTrials":62,"cells":1237},"cipralex",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1239,"activeCount":66},[],{"trials":1241,"activeCount":66},[],{"trials":1243,"activeCount":66},[],{"trials":1245,"activeCount":66},[],{"trials":1247,"activeCount":66},[],{"trials":1249,"activeCount":66},[1250],{"nctId":1251,"briefTitle":1252,"status":189,"phases":1253,"primaryCompletion":1254,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1259},"NCT01644071","Serotonergic System and Violent Video Games",[59],"2014-02","2014-06","2012-02",47,[781],[1236],{"intervention":1261,"totalTrials":62,"cells":1262},"Velphoro",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1264,"activeCount":66},[],{"trials":1266,"activeCount":66},[],{"trials":1268,"activeCount":66},[],{"trials":1270,"activeCount":66},[],{"trials":1272,"activeCount":66},[],{"trials":1274,"activeCount":66},[1275],{"nctId":1276,"briefTitle":1277,"status":314,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT03409757","Velphoro and Impact on the Oral Cavity and Gut Microbiome",[],"2020-10-06","2018-02-28",22,[1283],"Hyperphosphatemia",[1261],{"intervention":1286,"totalTrials":62,"cells":1287},"Vitamin K supplement",{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1289,"activeCount":66},[],{"trials":1291,"activeCount":66},[],{"trials":1293,"activeCount":66},[],{"trials":1295,"activeCount":66},[],{"trials":1297,"activeCount":66},[],{"trials":1299,"activeCount":66},[1300],{"nctId":1301,"briefTitle":1302,"status":189,"phases":1303,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT05360342","Incorporation of Vitamin K Into Uremic Lipoproteins",[59],"2021-07-15","2021-09-15","2020-03-31",20,[1309],"Vitamin K Deficiency",[1286],{"intervention":1312,"totalTrials":62,"cells":1313},"Seroquel",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1315,"activeCount":66},[],{"trials":1317,"activeCount":66},[],{"trials":1319,"activeCount":66},[],{"trials":1321,"activeCount":66},[],{"trials":1323,"activeCount":66},[],{"trials":1325,"activeCount":66},[1326],{"nctId":1327,"briefTitle":1328,"status":189,"phases":1329,"primaryCompletion":1330,"completion":1331,"start":360,"enrollment":1332,"conditions":1333,"interventions":1335},"NCT01552837","Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology",[59],"2010-02","2010-12",33,[1334],"Bipolar Disorder",[1312],{"intervention":1337,"totalTrials":62,"cells":1338},"Quetiapine",{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1340,"activeCount":66},[],{"trials":1342,"activeCount":66},[],{"trials":1344,"activeCount":66},[],{"trials":1346,"activeCount":66},[],{"trials":1348,"activeCount":66},[],{"trials":1350,"activeCount":66},[1351],{"nctId":1352,"briefTitle":1353,"status":714,"phases":1354,"primaryCompletion":1355,"completion":1356,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT02451306","Effect of Quetiapine on Brain Activity Patterns in Patients With Heightened Risk of Bipolar Disorder",[59],"2017-05","2018-05","2015-06",54,[1360,1334],"Depression",[1337],{"intervention":1363,"totalTrials":62,"cells":1364},"Levosimendan",{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1366,"activeCount":66},[],{"trials":1368,"activeCount":66},[],{"trials":1370,"activeCount":66},[],{"trials":1372,"activeCount":66},[],{"trials":1374,"activeCount":66},[],{"trials":1376,"activeCount":66},[1377],{"nctId":1378,"briefTitle":1379,"status":216,"phases":1380,"primaryCompletion":1381,"completion":1381,"start":1382,"enrollment":66,"conditions":1383,"interventions":1386},"NCT03022877","Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions",[59],"2018-12","2017-06",[1384,1385],"Myocardial Infarction","Outcome",[1363]]